Candriam SCA’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-256,198
| Closed | -$6.09M | – | 842 |
|
|
2020
Q2 | $6.09M | Buy |
256,198
+157,898
| +161% | +$2.2M | 0.06% | 298 |
|
|
2020
Q1 | $2.29M | Hold |
98,300
| – | – | 0.03% | 505 |
|
|
2019
Q4 | $2.35M | Sell |
98,300
-96,000
| -49% | -$2.65M | 0.03% | 519 |
|
|
2019
Q3 | $5.21M | Hold |
194,300
| – | – | 0.07% | 306 |
|
|
2019
Q2 | $5.25M | Hold |
194,300
| – | – | 0.07% | 321 |
|
|
2019
Q1 | $6.74M | Buy |
194,300
+30,000
| +18% | +$866K | 0.09% | 261 |
|
|
2018
Q4 | $3.21M | Hold |
164,300
| – | – | 0.05% | 364 |
|
|
2018
Q3 | $4.38M | Buy |
164,300
+18,600
| +13% | +$607K | 0.06% | 346 |
|
|
2018
Q2 | $5.5M | Buy |
145,700
+25,200
| +21% | +$964K | 0.09% | 279 |
|
|
2018
Q1 | $3.94M | Hold |
120,500
| – | – | 0.07% | 333 |
|
|
2017
Q4 | $5.87M | Sell |
120,500
-8,000
| -6% | -$405K | 0.1% | 242 |
|
|
2017
Q3 | $6.94M | Sell |
128,500
-2,000
| -2% | -$117K | 0.12% | 209 |
|
|
2017
Q2 | $7.33M | Buy |
130,500
+50,000
| +62% | +$2M | 0.14% | 183 |
|
|
2017
Q1 | $3.15M | Sell |
80,500
-4,500
| -5% | -$143K | 0.06% | 355 |
|
|
2016
Q4 | $1.91M | Buy |
85,000
+9,100
| +12% | +$178K | 0.04% | 381 |
|
|
2016
Q3 | $1.72M | Buy |
75,900
+11,400
| +18% | +$268K | 0.04% | 387 |
|
|
2016
Q2 | $1.52M | Sell |
64,500
-12,000
| -16% | -$296K | 0.04% | 355 |
|
|
2016
Q1 | $1.55M | Sell |
76,500
-1,600
| -2% | -$50.8K | 0.04% | 361 |
|
|
2015
Q4 | $4.02M | Buy |
78,100
+10,000
| +15% | +$485K | 0.11% | 207 |
|
|
2015
Q3 | $2.9M | Sell |
68,100
-20,900
| -23% | -$1.01M | 0.07% | 287 |
|
|
2015
Q2 | $4.05M | Sell |
89,000
-71,000
| -44% | -$2.86M | 0.08% | 273 |
|
|
2015
Q1 | $6.08M | Buy |
+160,000
| New | +$5.5M | 0.12% | 221 |
|
Candriam SCA's PTLA Position: Q3 2020 in Review
Candriam SCA sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 256,198 shares — an estimated $6.09M sold.
Candriam SCA first reported a position in PTLA in Q1 2015 and held it in 22 quarters. The position peaked at $7.33M in Q2 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Candriam SCA reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Candriam SCA sold 256,198 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $6.09M.
- Candriam SCA first reported a position in Portola Pharmaceuticals, Inc. in Q1 2015 and held it in 22 quarters.
- Candriam SCA's Portola Pharmaceuticals, Inc. position peaked at $7.33M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Candriam SCA's 13F filing for Q3 2020, filed 19 Oct 2020.